Recently, programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) inhibitors (alone or in combination) have been shown to result in higher survival rates than standard chemotherapy in patients with advanced NSCLC.2, 3, 4, 5, 6, 7, 8. This evidence concerns the gene CD274 and non-small cell lung carcinoma.